Clinical trial

Natalizumab Re-Initiation of Dosing

NCT00306592

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-03-01

PhasePHASE3

Study timeline

Study start (unknown)2006-03-01Date precision: month

Registry last updated2017-03-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosis, Relapsing-Remittingunresolved

Interventions

BG00002 (natalizumab)BIOLOGICAL

Sponsors & collaborators

Biogenlead sponsor

Elan Pharmaceuticalscollaborator

Mapped research locations

New YorkNew York, United States2 ChicagoIllinois, United States2 PhiladelphiaPennsylvania, United States2 PittsburghPennsylvania, United States2 Los AngelesCalifornia, United States1 DallasTexas, United States1 BaltimoreMaryland, United States1 AtlantaGeorgia, United States1 MiamiFlorida, United States1 TorontoOntario, Canada1 NashvilleTennessee, United States1 San FranciscoCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00306592 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.